Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation - Novartis

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation  NovartisNovartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week  CNBCNovartis pens $2B deal for allergy biotech with potential Xolair successor  Fierce BiotechNovartis to pay up to $2 billion for US biotech firm Excellergy  ReutersNovartis to buy U.S.-based biotech firm Excellergy for up to $2 billion  Yahoo Finance